Summary and Key Points on Russia's Latest Fighter Jet Failure: The MiG-35 "Fulcrum-F" was once hailed as Russia's next-generation fighter, but its capabilities have proven underwhelming.

The most widely flown Russian aircraft is not actually any single MiG fighter jet, instead it’s the Mi-8/17/171 Hip ... much ...

Fulcrum Bioenergy, which once sought to invest $600 million in a Gary facility that would turn household waste into a more sustainable form of jet fuel, filed for Chapter 11 bankruptcy ...

Fulcrum Therapeutics (NASDAQ:FULC) announced Thursday after its lead program for protein kinase inhibitor losmapimod, in-licensed from GSK (GSK), failed to reach main goals in patients with a rare ...

France has announced details of its plans to put surplus Dassault Mirage 2000 fighters into Ukrainian hands, with these jets ...

Jet, a flat-black, opaque gemstone derived from wood that has experienced extreme compression over millions of years, was the haute stone throughout the Victorian era, a time when fashion and ...

Fulcrum Therapeutics, Inc.'s stock plummeted over 60% after its lead candidate, losmapimod, failed to meet primary and secondary endpoints in a Phase 3 study for FSHD. Despite prior optimism and ...

Just four months after Sanofi bet $80 million in upfront cash on Fulcrum Therapeutics’ losmapimod, the program has ended in a phase 3 failure. The licensing deal with the Big Pharma was agreed ...

Fulcrum Therapeutics Inc. (NASDAQ:FULC) stock is trading lower on Thursday after the company released data from the Phase 3 REACH trial evaluating losmapimod in patients with Facioscapulohumeral ...

Losmapimod failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48 ― ― Fulcrum to suspend future losmapimod development ...

The latest is a company called Twelve, which raised $645 million from backers including the private-equity firm TPG and Alaska Airlines in one of the largest investments ever for clean jet fuel.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...